Literature DB >> 19877730

Clinical aspects of invasive candidiasis in critically ill patients.

Mariano Pennisi1, Massimo Antonelli.   

Abstract

Invasive candidiasis has emerged as an important cause of morbidity and mortality in intensive care unit patients. This short review focuses on many aspects of Candida infection in critically ill patients including epidemiology, impact on mortality, problems related to diagnosis, strategies to identify patients at risk of developing fungal infections, role of prophylaxis and pre-emptive strategies, empiric treatment and the role of different classes of antifungal drugs. New antifungal agents, specifically new azoles and echinocandins are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19877730     DOI: 10.2165/11315590-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  44 in total

1.  Echinocandins--first-choice or first-line therapy for invasive candidiasis?

Authors:  Jack D Sobel; Sanjay G Revankar
Journal:  N Engl J Med       Date:  2007-06-14       Impact factor: 91.245

Review 2.  Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients.

Authors:  Ercole Concia; Anna Maria Azzini; Michela Conti
Journal:  Drugs       Date:  2009       Impact factor: 9.546

3.  Clinical significance of Candida isolated from peritoneum in surgical patients.

Authors:  T Calandra; J Bille; R Schneider; F Mosimann; P Francioli
Journal:  Lancet       Date:  1989-12-16       Impact factor: 79.321

4.  Candida glabrata fungemia: experience in a tertiary care center.

Authors:  Anurag Malani; Jareer Hmoud; Loretta Chiu; Peggy L Carver; Andrew Bielaczyc; Carol A Kauffman
Journal:  Clin Infect Dis       Date:  2005-08-24       Impact factor: 9.079

5.  Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.

Authors:  B J Kullberg; J D Sobel; M Ruhnke; P G Pappas; C Viscoli; J H Rex; J D Cleary; E Rubinstein; L W P Church; J M Brown; H T Schlamm; I T Oborska; F Hilton; M R Hodges
Journal:  Lancet       Date:  2005 Oct 22-28       Impact factor: 79.321

6.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

Review 7.  The echinocandins.

Authors:  Diane Cappelletty; Kasi Eiselstein-McKitrick
Journal:  Pharmacotherapy       Date:  2007-03       Impact factor: 4.705

8.  Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial.

Authors:  Mindy G Schuster; John E Edwards; Jack D Sobel; Rabih O Darouiche; Adolf W Karchmer; Susan Hadley; Gus Slotman; Helene Panzer; Pinaki Biswas; John H Rex
Journal:  Ann Intern Med       Date:  2008-07-15       Impact factor: 25.391

9.  In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

10.  A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

Authors:  John H Rex; Peter G Pappas; Adolf W Karchmer; Jack Sobel; John E Edwards; Susan Hadley; Corstiaan Brass; Jose A Vazquez; Stanley W Chapman; Harold W Horowitz; Marcus Zervos; David McKinsey; Jeannette Lee; Timothy Babinchak; Robert W Bradsher; John D Cleary; David M Cohen; Larry Danziger; Mitchell Goldman; Jesse Goodman; Eileen Hilton; Newton E Hyslop; Daniel H Kett; Jon Lutz; Robert H Rubin; W Michael Scheld; Mindy Schuster; Bryan Simmons; David K Stein; Ronald G Washburn; Linda Mautner; Teng-Chiao Chu; Helene Panzer; Rebecca B Rosenstein; Jenia Booth
Journal:  Clin Infect Dis       Date:  2003-05-08       Impact factor: 9.079

View more
  2 in total

1.  Conclusions. Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections.

Authors:  Pasquale De Bellis
Journal:  Drugs       Date:  2009       Impact factor: 9.546

2.  1-Aryl-3-(1H-imidazol-1-yl)propan-1-ol esters: synthesis, anti-Candida potential and molecular modeling studies.

Authors:  Mohamed I Attia; Awwad A Radwan; Azza S Zakaria; Maha S Almutairi; Soraya W Ghoneim
Journal:  Chem Cent J       Date:  2013-10-25       Impact factor: 4.215

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.